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The Overview series
This publication series from the Drug Misuse Research Division (DMRD) 
of the Health Research Board (HRB) provides a comprehensive review of 
specific drug-related issues in Ireland. Each issue in the series will examine, 
in an objective and reliable manner, an aspect of the drugs phenomenon. It 
is envisaged that each issue will be used as a resource document by policy 
makers, service providers, researchers, community groups and others 
interested in the drugs area.
Drug Misuse Research Division
The Drug Misuse Research Division (DMRD) is a multi-disciplinary team 
of researchers and information specialists who provide objective, reliable 
and comparable information on the drug situation, its consequences and 
responses in Ireland. The DMRD maintains two national drug-related 
surveillance systems and is the national focal point for the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The 
Division also manages the National Documentation Centre on Drug Use. 
The DMRD disseminates research findings, information and news in 
Occasional Papers, in the Overview series, and in the quarterly newsletter 
Drugnet Ireland. Through its activities, the DMRD aims to inform policy 
and practice in relation to drug use.
Health Research Board
The HRB is a statutory body with a mission to improve health through 
research and information. The HRB is responsible for promoting, 
commissioning and conducting medical, epidemiological and health 
services research in Ireland. The HRB carries out these roles, and adds 
value, through competitive funding of health research, participation in 
health research and maintaining national research databases on disability, 
mental health and drug misuse.
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Glossary of terms
Incidence is a term used to describe the number of new cases of disease or 
events that develop among a population during a specified time interval.  
For example, in 2001, ten opiate users living in a specific county sought 
treatment for the first time.  The incidence is the number of opiate cases 
divided by the population living in the county (say 31,182 persons in this 
example) expressed per given number of the population, i.e., per 100, per 
1,000, per 10,000, etc.
The calculation in this case is as follows: (10/31,182) x 10,000, which 
gives an incidence rate of 3.2 per 10,000 of the specific county population 
in 2001.
Prevalence is a term used to describe the proportion of people in a 
population who have a disease or condition at a specific point or period 
in time.  For example, in 2001, ten opiate users living in a specific county 
sought treatment for the first time, 20 opiate users returned to treatment 
in the year and five opiate users continued in treatment from the previous 
year; in total there are 35 people treated for problem opiate use in 2001.  
The prevalence is the total number of cases (35) divided by the population 
living in the county (31,182 persons) expressed per given number of the 
population, i.e., per 100, per 1,000, per 10,000, etc. 
The calculation in this case is as follows: (35/31,182) x 10,000, which 
gives a prevalence rate of 11.2 per 10,000 of the specific county 
population in 2001.
A confidence interval is the range of values (for example, proportions) 
in which the true value is likely to be found.  By convention, a 95% 
confidence interval is usually calculated, that is, the range of values will 
include the true value 95% of the time. 
In relation to hepatitis C, the polymerase chain reaction (PCR) test assesses 
whether the virus is still detectable in the blood and will show if a person 
has an ongoing infection.
10 Drug Misuse Research Division 
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1  Summary
The data presented in this publication describe what is known about 
blood-borne viral infections among drug users in Ireland.  The data 
pertaining to injecting drug users are presented where possible, and where 
the data are not analysed by injecting status or where injecting status is not 
ascertained, the data on all drug users are presented. 
The current and potential sources of data in Ireland on blood-borne viral 
infections are described.  
The analysis presented in this Overview is based on disease notifications 
reported to the Health Protection Surveillance Centre (formerly known as 
the National Disease Surveillance Centre) during the period 1995 to 2005 
and on ad hoc research studies. 
This Overview will assist policy makers, service planners and public health 
practitioners to develop further appropriate responses to some of the 
consequences of injecting drug use.
The main observations and their implications are: 
The number of newly diagnosed cases of HIV among injecting drug users 
increased in 1999 and to date has remained at a higher level than in the 
early nineties, while the number of new AIDS cases diagnosed decreased.  
Around one-tenth of injecting drug users in drug treatment are HIV 
positive. Age, injecting practices and sexual practices are associated with 
HIV status. The increase in HIV infections over the last five years requires 
investigation. HIV treatment (HAART) is available to injecting drug users 
through genito-urinary medical units and infectious disease clinics in 
Ireland. In 2003, a study reported that a number of stable injecting drug 
users were suitable for treatment, but were not receiving treatment at the 
time of the study.  Two studies demonstrated that decentralised treatment 
at drug treatment centre level achieved high uptake and compliance with 
HIV treatment.  
Just under one-fifth of injecting drug users in treatment have ever been 
infected with hepatitis B and approximately 2% are chronic cases. Age, 
injecting practices and sexual practices are linked to hepatitis B status.  
The uptake and completion rates of hepatitis B vaccination are much 
higher in the HSE South Western Area (56%) and in Drug Treatment 
Centre Board (86%) cohorts for the period 2001 to 2003 than those 
reported in prisoners or at general practice in Ireland between 1998 and 
2001. This possibly indicates an increase in hepatitis B vaccine coverage 
in recent years. There are no published data on the coverage of hepatitis B 
vaccine among injecting drug users outside the HSE Eastern Region.   
It is important to ensure that hepatitis B vaccine is administered as early 
as possible in a drug user’s career; therefore, needle exchange and low-
threshold methadone services require facilities to deliver this intervention 
on a daily basis.  
Around 70% of injecting drug users attending drug treatment tested 
positive for antibodies to the hepatitis C virus. Injecting practices and 
prison history are associated with hepatitis C status. There are seven 
specialist hepatology centres for adults and one for children in Ireland. 
A number of studies demonstrated low rates of access to and uptake of 
treatment for hepatitis C among injecting drug users. Two small studies 
demonstrated that a decentralised approach to initial assessment at general 
practice level and hepatitis C treatment at drug treatment centres achieved 
higher uptake and compliance rates than the current centralised approach.  
Little has been published in Ireland on the prevalence of co-infection 
with HIV and/or hepatitis B and/or hepatitis C.  The two national prison 
surveys in the late nineties presented data on co-infection among prisoners. 
These data indicated that approximately one-fifth of prisoners testing 
positive for hepatitis C were also infected with either hepatitis B or HIV. 
Up-to-date information is required. 
Both HIV co-infection and, independently, high rates of alcohol 
consumption among those infected with hepatitis C are associated with 
more rapid disease progression and higher death rates.  
14 Drug Misuse Research Division 
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The principles of expanded and accessible harm reduction measures are 
documented in both the AIDS Strategy 2000 and the Mid-Term Review 
of the National Drugs Strategy and will lead to synergistic actions to stem 
the current increase in new HIV cases among injecting drug users. The 
publication of the HSE Eastern Region’s hepatitis C strategy is awaited.  
Newly diagnosed HIV cases are reported directly to the Health Protection 
Surveillance Centre (HPSC) through a case-based, extended surveillance 
system and staff at the HPSC collate these data on a six-monthly basis.  
Up to 2005, information on risk factors was not included in the data 
recorded on newly diagnosed cases of hepatitis B and hepatitis C, which 
makes it difficult to monitor the number of newly diagnosed cases of these 
infectious diseases among injecting drug users.  It also means that Ireland 
has been unable to provide data to the European Monitoring Centre for 
Drugs and Drug Addiction on the incidence of hepatitis B and hepatitis 
C among injecting drug users. Action 39 of the European Union Drugs 
Action Plan requires member states to comply with the requirements of the 
key indicators to measure the drug situation. The incidence and prevalence 
of HIV, hepatitis B and hepatitis C among injecting drug users is one of the 
five key indicators. In recent years, the HPSC has improved the reporting 
of newly diagnosed cases of hepatitis B and hepatitis C. In 2006, hepatitis 
B data by risk factor status will be published.  
There are a number of areas where further research is required. The data 
presented in this Overview indicate the need to record the risk factor 
status of newly diagnosed cases of hepatitis C.  There is a need to set up 
a register to quantify the incidence and prevalence of hepatitis C among 
all heroin and cocaine users, including those who are in harm reduction 
and treatment services. The register should also permit the assessment 
of main risk factors (including drug-administration routes and prison 
exposure), treatment uptake and outcomes. Strategies to increase uptake 
of and compliance with HIV and hepatitis C therapy in both prison and 
community settings need to be implemented and monitored. The medical 
consequences of and interventions required to deal with hepatitis C 
1 Summary
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among injecting drug users need to be estimated. A system to monitor the 
national hepatitis B vaccine uptake is required to estimate coverage among 
prisoners, injecting drug users and sex workers.  The effectiveness of needle 
exchange, opiate detoxification and opiate maintenance programmes in 
stabilising and reducing the incidence of hepatitis C needs to be quantified. 
Blood-borne viral infections among injecting 
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2  Introduction
HIV, hepatitis B and hepatitis C are three blood-borne viruses that can be 
acquired through illicit injecting drug use.  All three infections can lead to 
serious medical consequences.  This overview is a synthesis of published 
research on blood-borne viral infections associated with injecting drug 
use. In the case of each infection, the facts known about the background, 
incidence, prevalence, risk factors, treatment and prevention are presented. 
With the exception of background and treatment, the review of issues is 
based substantially on the Irish literature. The current policy and strategy 
in Ireland pertaining to each infection are also reviewed.  Gaps in current 
knowledge are identified and information-collection measures to fill 
these gaps are suggested.  In order to permit the individual sections of 
the Overview on HIV, hepatitis B and hepatitis C to be read as separate 
papers, there is some repetition in each of these sections.  
HIV is not a notifiable disease, but voluntary linked testing for antibodies 
to HIV was available in Ireland between 1985 and 2001; risk-factor 
status (such as injecting drug use) was recorded. Since July 2001, newly 
diagnosed HIV cases are reported through a case-based reporting system. 
The case-based system provides disaggregated data on all new HIV-positive 
cases.  Important changes to infectious disease legislation were introduced 
in Ireland on 1 January 2004. The Infectious Diseases Regulations 1981 
were amended to establish a revised list of notifiable diseases and, for the 
first time, their causative pathogens.1 Case definitions were introduced 
for the first time in Ireland. Under the revised legislation, laboratory 
directors, as well as clinicians, are now required to report the named 
notifiable diseases. Except for the non-inclusion of HIV, the changes to 
the list of notifiable diseases are consistent with a European Commission 
decision on communicable diseases.2  Hepatitis B has been on the list of 
notifiable diseases since 1981; the 2004 amendment to include laboratory 
directors as a source of notification was intended to increase the number 
and coverage of notifications.  The inclusion of hepatitis C as a notifiable 
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disease (from 2004 onwards) provides important data on newly diagnosed 
cases of hepatitis C in the general population.
The European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) identifies drug-related infectious diseases as one of the five 
key indicators of drug misuse in Europe. In each member state there is a 
focal point for the collation of indicator data; the focal point in Ireland is 
the Drug Misuse Research Division (DMRD) of the HRB.  The EMCDDA 
monitors the number of newly diagnosed cases (proxy for incidence) and 
prevalence of HIV, hepatitis B and hepatitis C among injecting drug users 
across Europe.  At present, Ireland is unable to provide data to Europe on 
the incidence of hepatitis B and hepatitis C because the risk factor status 
of hepatitis B cases was not recorded until 2005, and the risk factor data 
for hepatitis C is still unavailable.  Action 39 of the European Union Drugs 
Action Plan requires member states to comply with the requirements of 
the key indicators to measure the drug situation.3  Enhanced surveillance 
is essential to identify such risk factors and to inform planning, prevention 
and treatment strategies.  Risk-factor identification is required to fulfil 
the basic requirements of the EMCDDA’s key indicator on drug-related 
infectious diseases. 
Newly diagnosed HIV cases are reported directly to the Health Protection 
Surveillance Centre (HPSC) (formerly known as the National Disease 
Surveillance Centre) through a case-based, extended surveillance system, 
and staff at the HPSC collate these data on a six-monthly basis.  All cases 
of hepatitis B and hepatitis C in Ireland are notified to the directors of 
public health in the Health Service Executive (HSE). On a weekly basis, 
these medical officers submit such notifications to the HPSC.  
Blood-borne viral infections among injecting 
drug users in Ireland, 1995 to 2005
3 Data Sources

 Drug Misuse Research Division 23
3  Data sources
Published data were sought on the incidence, prevalence and risk factors 
for HIV, hepatitis B and hepatitis C among injecting drug users in Ireland 
between 1995 and 2005, with data from earlier time periods included 
where necessary. The data pertaining to injecting drug users are presented 
where possible, and where the data are not analysed by injecting status 
or where injecting status is not ascertained, the data on all drug users 
are presented. Where appropriate, parameters (such as incidence and 
prevalence) were compared between injecting drug users and other risk 
populations and the general population. Newly diagnosed cases were used 
as a proxy for incidence where surveillance data are reported. Among the 
sources searched were: Medline, the HPSC website and its publications, 
the National Documentation Centre on Drug Use and reference lists in 
relevant publications. The Cochrane Library and National Institute for 
Health and Clinical Excellence (NICE) guidelines were used to identify best 
practice in the treatment of each infection.   
Depending on the study objective, specific details were systematically 
extracted from each paper.  The data extracted from incidence and 
prevalence studies were: year published, study design, study population, 
sample size, prevalence or incidence rate and method of ascertaining 
infection status.  The data extracted from risk-factor studies were: 
year published, study design, study population, sample size and factors 
associated with testing positive for infection.  The current standard of 
care or treatment for infection was extracted from Cochrane reviews or 
NICE guidelines.  Using some of the sources listed above, all published 
research on access to and compliance with treatment for blood-borne 
viral infections in Ireland was reviewed.  Current Irish policy and strategy 
documents were also reviewed.  
The measures of infection reported in incidence and prevalence studies are 
explained in Table 1.  
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Table 1   Parameters used to classify HIV, hepatitis B and hepatitis C 
infection status in studies presented in this Overview
Blood-borne 
viruses 
Parameter Purpose and meaning of each test
HIV Antibodies to 
HIV (Anti-HIV)
Antibody presence indicates ever having been infected 
with HIV.
Hepatitis B Antibodies to 
hepatitis B  
core antigen 
(Anti-HBc) 
Antibody appears 1–2 months after initial infection 
and indicates hepatitis B viral infection. The current 
infection status may be acute, chronic or resolved. This 
is a marker of current or past infection with hepatitis B.
Hepatitis B 
surface antigen 
(HBsAg)
Antigen appears 1 month following exposure and a 
continued presence for six months or more indicates 
a chronic infection.  Between 1% and 10% of adults 
who are infected with hepatitis B develop a chronic 
infection.
Antibodies 
to hepatitis B 
surface antigen 
(Anti-HBsAg)
Antibody presence indicates a vaccine-induced 
immunity or a spontaneous recovery from infection.
Hepatitis C Antibodies to 
the hepatitis C 
virus (Anti-HCV)
Antibody appears 3–6 months after initial infection and 
indicates previous or current hepatitis C viral infection. 
The current infection status may be acute, chronic or 
resolved. This is a marker of current or past infection 
with hepatitis C.
 Hepatitis C virus 
RNA PCR 
The PCR test assesses whether the hepatitis C virus is 
still detectable in the blood and will show if a person 
has a current infection.
Blood-borne viral infections among injecting 
drug users in Ireland, 1995 to 2005
4 HIV

 Drug Misuse Research Division 27
4  HIV
4.1 Introduction
This section presents an overview of published research on HIV associated 
with injecting drug use. The background, incidence, prevalence, risk 
factors, treatment and prevention are presented. With the exception of 
background and treatment, the review of issues is based substantially on 
the Irish literature. 
4.2 Background
HIV (subsequently known as HIV1) was identified in 1981 and HIV2 
was identified in 1986. The virus attaches itself to the CD4 particle 
of the T-lymphocytes. These T-lymphocytes co-ordinate the body’s 
immune response. HIV may lead to a condition known as acquired 
immunodeficiency syndrome (AIDS). This condition generally occurs 
when the CD4 count is below 200 per millilitre and is characterised by the 
appearance of opportunistic infections. Such infections take advantage of 
a weakened immune system. The HIV virus is found in all body fluids and 
is transmitted via sexual intercourse (both heterosexual and homosexual), 
mother to foetus and baby, infected blood and blood products and 
procedures with unsterile needles, syringes and skin-piercing instruments. 
Best evidence available to date indicates that once an individual is infected 
he or she remains infected for life.  
4.3 Newly diagnosed HIV cases 
Voluntary linked testing for antibodies to HIV has been available in 
Ireland since 1985.  By the end of 2005, there were 4,082 diagnosed HIV 
cases in Ireland, of which 1,270 (31%) were probably infected through 
injecting drug use.4 
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Figure 1 presents the number of new cases of HIV among injecting 
drug users, by year of diagnosis, reported in Ireland; data from 1982 to 
1985 were excluded from the figure as these four years were combined 
in the source records. The data presented in Figure 1 are based on data 
reported to the Department of Health and Children,5 the National Disease 
Surveillance Centre6 and the Health Protection Surveillance Centre.4,7 
Kelly and Clarke8 reported a fall in the number of HIV cases among 
injecting drug users between 1994 and 1998, with about 20 cases per year 
compared to about 50 cases each year in the preceding six years. In 1999, 
there was a sharp increase in the number of cases among injecting drug 
users, which continued into 2000, with 69 and 83 new cases respectively.9 
Between 2001 and 2003 there was a decline in the number of new injector 
cases (38, 50 and 49 respectively) when compared to 2000 but the number 
was higher than in 1998. In 2004, once again there was an increase (to 
71 cases) in the number infected through injecting drug use compared to 
the preceding three years.  In 2005 there were 66 cases infected through 
injecting drug use.  It was difficult to interpret the trend due to the 
relatively small numbers diagnosed each year, so a smoother curve (red line 
in Figure 1) was calculated using a rolling centred three-year average.  This 
curve presents an increase in the annual number of HIV cases in 1999; 
this higher number of cases was sustained between 2000 and 2004.  This 
indicates a true increase in the number of cases. 
Clarke and colleagues10 reviewed the demographic data of new HIV-
positive cases in Dublin diagnosed between January 1999 and December 
2000.  The authors reported that 40% of these cases were under 22 years 
old and that there was a clustering of cases in the Rialto (Dublin 8) area. 
Grogan and colleagues11 ascertained the prevalence and incidence of blood-
borne viral infections among heroin users attending methadone treatment 
services in the HSE South Western area (mainly the south western area 
of Dublin) in December 2001 by means of a retrospective review of 
participants’ clinical and laboratory records.  The researchers observed 
that there was a large pool of HIV-positive cases living in Dublin 8, while 
a very small number of HIV cases lived in Dublin 24 (E Keenan, personal 
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communication, 2003). Long et al.,12 using two existing data sources, 
developed a hypothesis that the risk of acquiring HIV and hepatitis C is 
associated with area of residence and may be linked to cocaine use. 
Of the 66 new HIV cases among injecting drug users reported to the 
Health Protection Surveillance Centre in 2005, 37 were male and 29 were 
female and the average age was 30.5 years. Of the 60 cases for whom 
place of residence was known, 55 lived in the HSE Eastern Region. The 
authors of the report on the 2004 data highlighted the need to continue to 
promote the use of harm reduction measures among injecting drug users.  
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Between 1992 and 1998, Smyth et al.13 estimated the incidence of HIV 
among 100 injecting drug users in Dublin who had an initial negative 
test and a repeat test within nine months. The authors reported that the 
incidence of HIV was 0.7 per 100 person years (95% CI 0.1 to 2.5).    
Data on newly diagnosed case of AIDS and on deaths among those with 
AIDS are published every six months. The data presented in Figure 2 
are based on data reported to the Department of Health and Children, 
the National Disease Surveillance Centre and the Health Protection 
Surveillance Centre. There were 846 cases of AIDS reported between 1983 
and 2004 (Figure 2).14 Of these, 316 (37%) reported that injecting drug 
use was a risk factor. Of these 316 cases, ten were men who had sex with 
men and injected drugs. Between 1983 and 1999, 78% of AIDS cases 
were resident in the Eastern Regional Health Authority area (now the HSE 
Eastern Region) and 15% were resident outside the area.5 
Figure 2   Number of new cases of AIDS among injecting drug users and 
others, by year of diagnosis, reported in Ireland, 1983 to 2004
Adapted from data reported to the Health Protection Surveillance Centre
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Therapy for the clinical management of persons with HIV has improved 
since the mid-1990s; as a result, the proportion of HIV cases developing 
AIDS decreased substantially between 1996 and 2000. Of the 846 AIDS 
cases between 1983 and 2004, 394 (46%) had died by the end of 2004. 
Of the 316 cases who had injecting drug use as a risk factor between 1983 
and 2004, 173 (55%) died. Of those diagnosed with AIDS, the proportion 
of HIV-positive injecting drug users who died (55%) was higher than that 
of heterosexuals (26%) and that of men who had sex with men (47%). 
This indicates a probable lower survival rate among injecting drug users 
with HIV compared to counterparts with other risk practices.
4.4  Prevalence
Blood donors and antenatal women, who are routinely tested for blood-
borne viral infections, may be used as proxy groups for the general 
population.
The prevalence of HIV was almost six per 100,000 (0.006%) new blood 
donors living in Dublin between 1996 and 2001 (E Lawlor, personal 
communication, 2003). In April 1999, the Department of Health and 
Children, on the advice of the National AIDS Strategy Committee, 
introduced a policy of voluntary antenatal HIV testing in Ireland. As 
part of this programme, it is recommended that HIV testing be offered to 
all women who attend antenatal services. A system for monitoring and 
evaluating the routine antenatal testing programme was established in July 
2001. Data are available from 2002 to 2004. The rate of HIV infection 
among pregnant women seeking antenatal care decreased from 0.31% in 
2003 to 0.25% in 2004.15
Just over 1% of the new attendees registered at Trinity Court Drug 
Treatment Centre tested positive for HIV antibodies (Table 2). In a cohort 
of injectors attending Eastern Health Board (now the HSE Eastern Region) 
methadone clinics in 1997, the prevalence of HIV antibodies, based on 
laboratory reports, was 17%. Among heroin users attending methadone 
4 HIV
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substitution services in a general practice setting in Dublin, Kildare and 
Wicklow, 8.7% had a documented HIV-positive status. Among opiate 
users in opiate treatment between 2001 and 2003, 11% to 12% tested 
positive for HIV.  The prevalence of HIV in the overall Irish prison 
population was lower than expected (at 2%). However, the prevalence of 
HIV among injector-inmates was 3.5%; this is 583 times greater than that 
among new blood donors and 14 times greater than that among women 
attending antenatal services, indicating the excess risk among injecting 
drug users. 
4.5  Risk factors
In 1991, 55% of 106 injecting drug users attending needle exchange 
reported that they had either lent or borrowed needles in the month 
prior to the survey. Although not statistically significant, 88% of those 
who tested positive for HIV had shared needles in the month prior to 
the survey, compared to 51% of HIV-negative respondents.16 In 1997, 
186 injecting drug users who attended a drug treatment centre in Dublin 
reported several high-risk behaviours: 56% shared needles and, of these, 
94% reported cleaning their equipment; however, less than half of them 
had cleaned their equipment effectively.17 The authors of this study did not 
investigate whether these risk factors were associated with testing positive 
for HIV.
In more recent studies, older injectors were more likely to test positive for 
HIV than their younger counterparts (Table 3). Length of injecting history 
and needle-sharing status were also associated with testing positive for 
HIV (Table 3). 
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4.6 Screening, treatment and prevention
HIV screening is conducted at drug treatment services and in the prison 
health service.  Grogan et al.11 estimated that 86% of clients attending 
drug treatment services in the HSE South Western Area had been tested for 
anti-HIV antibodies by December 2001.  
There is currently no vaccine and no cure for this viral infection. The 
current standard of care for individuals who have HIV is a combination of 
highly active antiretroviral therapies commonly referred to as HAART.24,25 
Specialists recommend that this be commenced at an early stage of the 
infection and tailored to the individual’s needs. 
HIV treatment (HAART) is available to injecting drug users through 
genito-urinary medical units and infectious disease clinics in Ireland. 
Three treatment sites are situated in Dublin hospitals (St James’s Hospital, 
Beaumont Hospital, and Mater Misericordiae Hospital), a fourth is based 
in University College Hospital, Cork, and a fifth in University College 
Hospital, Galway.26
As demonstrated in the study by Clarke et al.,27 access to and uptake 
of treatment for HIV is better than that for hepatitis C among injecting 
drug users in the eastern region of Ireland, but remains far from ideal. 
The authors report that it is assumed (without significant evidence) that 
injecting drug users are unlikely to comply with treatment. These authors 
interviewed 150 clients who attended the Genito-Urinary Medicine and 
Infectious Diseases Department (GUIDE clinic) in St James’s Hospital. 
All were HIV positive and had at some time injected drugs. Only 57% 
were receiving antiretroviral therapy. Of the 65 who were not receiving 
antiretroviral therapy, 50% fulfilled the standard criteria to commence 
therapy. This indicates that over 30 clients were suitable for treatment and 
were not receiving treatment at the time of the study. Compliance with 
HAART was associated with regular attendance at methadone treatment.
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In Dublin, Clarke and Mulcahy28 adapted the directly observed treatment 
approach (recommended by the World Health Organization (WHO) for 
the management of tuberculosis) in order to increase compliance with 
antiretroviral therapy among injecting drug users attending clinics for 
methadone maintenance. Each individual treated received a combination 
of medication tailored to his or her needs, administered in a daily or 
twice-daily dose.  Of the 39 study participants, 90% were complying with 
treatment at three months, 80% at six months and 69% at 12 months. 
The authors acknowledged that they had no comparison group with which 
to compare their results; however, the compliance rates achieved in this 
study were in line with the international experience of compliance with 
directly observed tuberculosis treatment among the general population. 
In a subsequent study,29 a higher level of compliance with antiretroviral 
therapy was reported among those attending methadone treatment services 
than among those not attending such services. 
In relation to injecting drug users, the AIDS Strategy 200030 recommended 
that data on the HIV status of treated injecting drug users continue to be 
captured. According to this strategy document, drug treatment centres are 
important sites for the provision of HIV risk counselling, health education 
and other prevention messages.  In order to increase the provision of these 
interventions, the strategy proposed a review of the role of counsellors with 
a view to expanding it to include HIV prevention.  The strategy confirmed 
that methadone treatment would continue to be a central element in the 
range of treatment options for opiate users and recommended that the HSE 
continue to expand treatment and harm reduction services (including needle 
exchange).  It recommended that the issue of homelessness among injecting 
drug users with HIV be addressed.  In addition, the recommendations of 
the reports on hepatitis B, hepatitis C and HIV among Irish prisoners31, 32 
will be explored (by the strategy group) in order to prevent the spread of 
such infections in this environment.  According to the strategy document, 
the range of services available to prevent and treat HIV in the community 
should also be available in prisons.  
4 HIV
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4.7 Policy and strategy
The 2005 mid-term review of the National Drugs Strategy introduced 
specific performance indicators on harm reduction for the first time in 
Ireland.33  These indicators are:
 •  Harm reduction facilities available, including needle exchange where 
necessary, open during the day, and at evenings and weekends, 
according to need, in every local health office area; and
 •  Incidence of HIV in [injecting] drug users stabilised, based on 2004 
figures.
The principles of expanded and easily accessible harm reduction services 
are common to both strategies and will lead to synergistic actions 
to stem the current increase in new HIV cases among injecting drug 
users.  The Irish Prison Service has published a number of documents 
promoting health and drug treatment services in Irish prisons.  The first 
recommendation in the report of the review group on the structure and 
organisation of prison services, published in 2001, is that similar care and 
treatment should be available in both the prison and community health 
services.34 In order to implement this recommendation, considerable 
groundwork was undertaken during 2004 to develop formal service 
agreements in a number of areas.35 For example, formal agreements were 
developed between Cloverhill and Wheatfield prison services and the 
health sector in order to provide consultant-led infectious disease and drug 
treatment services at these prisons from 2005 onwards. 
The Irish Prison Service published its drugs policy and strategy in May 
2006.36 According to this strategy, there will be a close link between 
drug treatment services and other health care services to ensure adequate 
management of mental illnesses and blood-borne viral diseases. The 
strategy lists a number of treatment approaches for those who stop using 
drugs, but has no harm-reduction measures for injecting drug users who 
continue to use drugs. The treatment approaches will be adapted for 
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prisoners with special needs, including drug users with mental health 
problems or hepatitis C.
4.8 Conclusions
Newly diagnosed HIV cases are reported directly to the Health Protection 
Surveillance Centre (HPSC) (formerly known as the National Disease 
Surveillance Centre) through a case-based, extended surveillance system 
and staff at the HPSC collate these data on a six-monthly basis. The 
number of newly diagnosed cases of HIV among injecting drug users 
increased in 1999 and to date has remained at a higher level than in the 
early nineties, while the number of new AIDS cases diagnosed decreased.  
Around one-tenth of injecting drug users in drug treatment are HIV 
positive. Age, injecting practices and sexual practices are associated with 
HIV status. The increase in HIV infections over the last five years requires 
investigation. HIV treatment (HAART) is available to injecting drug users 
through genito-urinary medical units and infectious disease clinics in 
Ireland. In 2003, a study reported that a number of stable injecting drug 
users were suitable for treatment, but were not receiving treatment at the 
time of the study.  Two studies demonstrated that decentralised treatment 
at drug treatment centre level achieved high uptake and compliance with 
HIV treatment.  
 
4 HIV
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5 Hepatitis B
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5  Hepatitis B
5.1 Introduction
This section presents an overview of published research on hepatitis B 
associated with injecting drug use. The background, incidence, prevalence, 
risk factors, treatment and prevention are presented. With the exception of 
background and treatment, the review of issues is based substantially on 
the Irish literature. 
5.2 Background
Hepatitis B is an infection caused by the hepadnavirus. The incubation 
period usually lasts 6 to 26 weeks. The virus can be transmitted through 
blood, semen, vaginal secretions and saliva. The main routes for 
transmission are parenteral (through infected blood and blood products 
and contaminated needles and syringes), vertical (in utero or during 
childbirth) and sexual (particularly in those who engage in casual sex and 
in men who have sex with men). Between 1% and 10% of adults who 
are infected with hepatitis B develop a chronic infection. Hepatitis B virus 
is an important cause of liver disease, including acute hepatitis, chronic 
hepatitis, cirrhosis of the liver and primary hepatocellular carcinoma. 
5.3 Newly diagnosed hepatitis B cases
Hepatitis B is a notifiable disease in Ireland and cases should be reported 
to the public health departments of the HSE area where the case is 
resident. Research on the incidence of hepatitis B in the period 1970 
to 1987 clearly identifies the excess risk among injecting drug users in 
Ireland.37 A number of laboratories in Ireland can identify hepatitis B, 
but the majority of cases are diagnosed at the National Virus Reference 
Laboratory (NVRL). Data from the NVRL show the number of chronic 
cases of hepatitis B identified for the first time each year. Between 1990 
and 1996 there were about 100 cases identified for the first time each year. 
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From 1997 to 2000, there was a sharp increase in the number of cases 
identified for the first time; in 1997 there were 143 newly identified cases 
and in 2003 there were 547. Many of the newly identified cases were likely 
to be immigrants from moderate- to high-endemicity countries. In the HSE 
Southern Area between 2000 and 2002, 95% or more of hepatitis B cases 
diagnosed were asylum seekers from such countries.38 Between 1990 and 
2001, the numbers of notifications to the departments of public health 
were lower than the numbers of individuals who tested positive for the 
first time identified by the NVRL,39 but followed the same increasing trend 
over time. Notifications increased in recent years and this increase was 
notable before the introduction of the new infectious diseases legislation in 
2004 (Figure 3).40 Up to the end of 2004, the notification system did not 
categorise cases by risk group or differentiate between new and previously 
diagnosed cases. 
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Figure 3   Numbers of hepatitis B cases notified to the Health Protection 
Surveillance Centre40 and hepatitis B (surface antigen positive) cases 
identified by the National Virus Reference Laboratory,39 1990 to 2004
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5.4 Prevalence
Hepatitis B prevalence is estimated using two markers in a person’s blood. 
The presence of one marker, antibodies to the hepatitis B core antigen, 
indicates that a person is or has ever been infected with the hepatitis B 
virus.  The presence of the second marker, hepatitis B surface antigen, 
indicates that a person has a chronic hepatitis B viral infection. The 
numbers with antibodies to hepatitis B core antigen are 10 to 100 times 
greater than the numbers who remain chronically infected with hepatitis B. 
The prevalence of chronic cases of hepatitis B in the general population 
in Ireland is low. Between 1996 and 2001, just less than 17 in 100,000 
(0.016%) new blood donors living in Dublin had a chronic hepatitis B 
infection (E Lawlor, personal communication, 2003). Between January 
1998 and June 2000, the prevalence of hepatitis B carriage among Irish-
born women attending antenatal services in a Dublin hospital was 0.03%; 
this was much lower than that reported among clients from countries 
outside the European Union attending the same antenatal service (4.0% 
to 5.3%).41 The prevalence among women attending antenatal services is 
almost twice that among new blood donors living in Dublin. The national 
population prevalence for past exposure to hepatitis B, based on a postal 
survey in 18 district electoral divisions using a multi-stage stratified-cluster 
sampling technique, was 0.5% (95% CI 0.0 –1.8).42 The prevalence among 
the general population was over three times that among new blood donors 
living in Dublin. 
The document Immunisation guidelines for Ireland 2002 identified six 
high-risk populations in Ireland: sex workers and individuals who change 
sexual partners frequently, injecting drug users, prisoners, tattoo artists, 
immigrants from and migrants to countries with high endemicity rates, and 
homeless people.43 Studies estimating the prevalence of blood-borne viruses 
among injecting drug users in Ireland tend to have been conducted using 
cohorts of drug users attending particular drug treatment services, or in the 
prison setting (Table 4). 
5 Hepatitis B
46 Drug Misuse Research Division 
Ta
b
le
 4
  
 R
ev
ie
w
 o
f 
st
u
d
ie
s 
es
ti
m
at
in
g
 t
h
e 
p
re
va
le
n
ce
 o
f 
h
ep
at
it
is
 B
 a
m
o
n
g
 d
ru
g
 u
se
rs
 i
n
 I
re
la
n
d
, 
1
9
9
8
 t
o
 2
0
0
5
Ye
ar
 
p
u
b
li
sh
ed
an
d
 a
u
th
o
rs
St
u
d
y 
d
es
ig
n
St
u
d
y 
p
o
p
u
la
ti
o
n
 
an
d
 s
am
p
le
 s
iz
e
St
u
d
y 
fi
n
d
in
g
s
M
et
h
o
d
 o
f 
as
ce
rt
ai
n
in
g
 
st
at
u
s
19
98
 S
m
yt
h 
 
et
 a
l.1
8
N
ew
 a
tt
en
de
es
 
re
gi
st
er
ed
 a
t 
Tr
in
ity
 C
ou
rt
 D
ru
g 
Tr
ea
tm
en
t 
C
en
tr
e 
in
 D
ub
lin
 b
et
w
ee
n 
19
92
 a
nd
 1
99
7
73
5 
in
je
ct
or
s 
liv
in
g 
in
 
D
ub
lin
 c
ity
1%
 t
es
te
d 
po
si
tiv
e 
fo
r 
H
Bs
A
g*
St
at
us
 
as
ce
rt
ai
ne
d 
fr
om
 
se
ru
m
20
00
 C
ul
le
n 
et
 a
l.1
9
Re
vi
ew
 o
f 
re
co
rd
s 
of
 
cl
ie
nt
s 
at
te
nd
in
g 
m
et
ha
do
ne
 
su
bs
tit
ut
io
n 
cl
in
ic
s 
in
 a
 g
en
er
al
 
pr
ac
tic
e 
se
tt
in
g
In
je
ct
or
s 
(4
57
) 
an
d 
no
n-
in
je
ct
or
s 
(7
8)
 li
vi
ng
 
in
 D
ub
lin
, K
ild
ar
e 
an
d 
W
ic
kl
ow
Sa
m
pl
e:
 5
35
 (
of
 w
ho
m
 
31
6 
ha
d 
th
ei
r 
he
pa
tit
is
 B
 
st
at
us
 r
ec
or
de
d)
O
f 
th
os
e 
w
ho
 h
ad
 h
ep
at
iti
s 
B 
st
at
us
 
re
co
rd
ed
 in
 t
he
ir 
cl
in
ic
al
 n
ot
es
, 1
3.
6%
 
ha
d 
a 
do
cu
m
en
te
d 
he
pa
tit
is
 B
 p
os
iti
ve
 
st
at
us
.
Th
e 
pr
im
ar
y 
ob
je
ct
iv
e 
of
 t
hi
s 
st
ud
y 
w
as
 
no
t 
to
 a
ss
es
s 
pr
ev
al
en
ce
 o
f 
he
pa
tit
is
 B
.
St
at
us
 
as
ce
rt
ai
ne
d 
fr
om
 
cl
in
ic
al
 n
ot
es
20
01
 A
llw
rig
ht
 
et
 a
l.2
1
C
ro
ss
-s
ec
tio
na
l 
su
rv
ey
 
Pr
is
on
 in
m
at
es
, o
f 
w
ho
m
 
50
9 
w
er
e 
in
je
ct
or
s
18
.5
%
 t
es
te
d 
po
si
tiv
e 
fo
r 
an
ti-
H
Bc
St
at
us
 a
sc
er
ta
in
ed
 
fro
m
 o
ra
l f
lu
id
20
01
 
Fi
tz
ge
ra
ld
  
et
 a
l.2
0
Re
vi
ew
 o
f 
re
co
rd
s 
of
 c
lie
nt
s 
at
te
nd
in
g 
fiv
e 
m
et
ha
do
ne
 c
lin
ic
s 
in
 D
ub
lin
64
 c
lie
nt
s,
 in
cl
ud
in
g 
in
je
ct
or
s 
an
d 
no
n-
in
je
ct
or
s
O
f 
th
os
e 
w
ho
 h
ad
 h
ep
at
iti
s 
B 
st
at
us
 
re
co
rd
ed
 in
 t
he
ir 
cl
in
ic
al
 n
ot
es
, 2
8.
1%
 
ha
d 
a 
do
cu
m
en
te
d 
po
si
tiv
e 
he
pa
tit
is
 
B 
co
re
 a
nt
ig
en
 s
ta
tu
s;
 5
.1
%
 h
ad
 a
 
do
cu
m
en
te
d 
H
Bs
A
g 
po
si
tiv
e 
st
at
us
.
St
at
us
 
as
ce
rt
ai
ne
d 
fr
om
 la
bo
ra
to
ry
 
re
po
rt
s 
or
 c
lin
ic
al
 
no
te
s
 Drug Misuse Research Division 47
Ta
b
le
 4
  
 R
ev
ie
w
 o
f 
st
u
d
ie
s 
es
ti
m
at
in
g
 t
h
e 
p
re
va
le
n
ce
 o
f 
h
ep
at
it
is
 B
 a
m
o
n
g
 d
ru
g
 u
se
rs
 i
n
 I
re
la
n
d
, 
1
9
9
8
 t
o
 2
0
0
5
 (
co
nt
in
ue
d)
Ye
ar
 
p
u
b
li
sh
ed
an
d
 a
u
th
o
rs
St
u
d
y 
d
es
ig
n
St
u
d
y 
p
o
p
u
la
ti
o
n
 
an
d
 s
am
p
le
 s
iz
e
St
u
d
y 
fi
n
d
in
g
s
M
et
h
o
d
 o
f 
as
ce
rt
ai
n
in
g
 
st
at
u
s
20
01
 L
on
g 
 
et
 a
l.2
2
C
ro
ss
-s
ec
tio
na
l 
su
rv
ey
Pr
iso
n 
en
tr
an
ts
, o
f w
ho
m
 
17
3 
w
er
e 
in
je
ct
or
s
17
.9
%
 t
es
te
d 
po
sit
iv
e 
fo
r 
an
ti-
H
Bc
.
St
at
us
 a
sc
er
ta
in
ed
 
fro
m
 o
ra
l f
lu
id
20
04
 
O
’S
ul
liv
an
 2
3
C
ro
ss
-s
ec
tio
na
l 
su
rv
ey
65
 in
je
ct
or
 o
pi
at
e 
us
er
s 
in
 
tr
ea
tm
en
t 
at
te
nd
in
g 
D
ru
g 
Tr
ea
tm
en
t 
C
en
tr
e 
Bo
ar
d
63
 in
je
ct
or
 o
pi
at
e 
us
er
s 
in
 
tr
ea
tm
en
t 
at
te
nd
in
g 
D
ru
g 
Tr
ea
tm
en
t 
C
en
tr
e 
Bo
ar
d
17
%
 t
es
te
d 
po
sit
iv
e 
fo
r 
an
ti-
H
Bc
;
0%
 t
es
te
d 
po
sit
iv
e 
fo
r 
an
ti-
H
Bs
Ag
.
St
at
us
 a
sc
er
ta
in
ed
 
fro
m
 s
er
um
20
05
 G
ro
ga
n 
et
 a
l.1
1
Re
tr
os
pe
ct
iv
e 
re
vi
ew
 o
f 
m
et
ha
do
ne
 c
lie
nt
s’
 
la
bo
ra
to
ry
 r
ec
or
ds
 
to
 D
ec
em
be
r 
20
01
 in
 t
he
 s
ou
th
-
w
es
te
rn
 a
re
a 
of
 
D
ub
lin
24
4 
op
ia
te
 u
se
rs
 in
 
m
et
ha
do
ne
 t
re
at
m
en
t;
29
9 
op
ia
te
 u
se
rs
 in
 
m
et
ha
do
ne
 t
re
at
m
en
t;
Th
es
e 
op
ia
te
 u
se
rs
 
in
je
ct
in
g 
st
at
us
 w
as
 n
ot
 
kn
ow
n
17
%
 t
es
te
d 
po
sit
iv
e 
fo
r 
an
ti-
H
Bc
.
2%
 t
es
te
d 
po
sit
iv
e 
fo
r 
H
Bs
Ag
.
St
at
us
 a
sc
er
ta
in
ed
 
fro
m
 la
bo
ra
to
ry
 
re
su
lts
* 
 A
 c
on
tin
ue
d 
pr
es
en
ce
 o
f 
he
pa
tit
is
 B
 s
ur
fa
ce
 a
nt
ig
en
 (
H
Bs
A
g)
 f
or
 s
ix
 m
on
th
s 
or
 m
or
e 
in
di
ca
te
s 
a 
ch
ro
ni
c 
or
 c
ar
rie
r 
st
at
us
. 
Be
st
 a
va
ila
bl
e 
ev
id
en
ce
 in
di
ca
te
s 
th
at
 t
he
 lo
ng
-t
er
m
 c
ar
rie
r 
ra
te
, a
nd
 h
en
ce
 in
fe
ct
iv
ity
, o
f 
so
m
eo
ne
 w
ho
 h
as
 e
ve
r 
be
en
 
in
fe
ct
ed
 w
ith
 h
ep
at
iti
s 
B 
is
 1
0%
 f
or
 a
du
lts
. 
 
 Th
e 
an
tib
od
y 
to
 h
ep
at
iti
s 
B 
co
re
 a
nt
ig
en
 (
an
ti-
H
Bc
) 
ca
n 
be
 f
irs
t 
de
te
ct
ed
 t
w
o 
to
 t
hr
ee
 w
ee
ks
 f
ol
lo
w
in
g 
in
fe
ct
io
n 
w
ith
 
he
pa
tit
is
 B
 v
iru
s 
an
d 
its
 p
re
se
nc
e 
in
di
ca
te
s 
ev
er
 h
av
in
g 
be
en
 n
at
ur
al
ly
 in
fe
ct
ed
 w
ith
 t
he
 v
iru
s.
48 Drug Misuse Research Division 
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From 1992 to 1997, 1% of new clients who attended Trinity Court Drug 
Treatment Centre tested positive for hepatitis B surface antigen. Among 
opiate users attending methadone substitution services in a general 
practice setting, 14% had a hepatitis B positive status documented in their 
clinical notes. In a cohort of opiate users attending Eastern Health Board 
(now the HSE Eastern Region) methadone clinics in the mid-nineties, 
the prevalence of hepatitis B surface antigen and antibodies to hepatitis 
B core antigen, based on laboratory reports or clinical notes, was 1.5% 
and 28% respectively. Two studies conducted between 2001 and 2003 
reported that 17% of problem opiate users attending methadone treatment 
in Dublin tested positive for antibodies to hepatitis B. Two studies 
estimated the prevalence of past exposure to hepatitis B among the Irish 
prisoner population; almost one-fifth of injector-inmates tested positive 
for antibodies to hepatitis B core antigen. The prevalence of hepatitis 
B carriage is five to seven times higher among injecting drug users than 
among women attending antenatal services, which provides an estimate 
of the excess risk among injecting drug users. Overall, the prevalence of 
hepatitis B among injecting drug users has remained lower than expected. 
There are two possible reasons for this: the small number of cases with 
chronic infection, and the proactive hepatitis B vaccination programme in 
Irish prisons and drug treatment settings. In Ireland there are no published 
estimates of hepatitis B prevalence among injecting drug users who attend 
needle exchanges or those who do not attend drug services. 
5.5 Risk factors
In 1998, Smyth et al.18 reported that injectors who commenced injecting 
drug use before 1990 were more likely to be chronic cases of hepatitis 
B than those who started injecting after 1990 (Table 5). Among Irish 
prisoners, injecting drug use was the most important risk factor for testing 
positive for antibodies to hepatitis B core antigen (Table 5). In the prison 
setting, injectors who were older and had been injecting longer were more 
likely to test positive for antibodies to hepatitis B core antigen than their 
younger, less exposed counterparts. These findings indicate that these older 
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cases may have contracted hepatitis B infection during the epidemic among 
injecting drug users in the 1980s.37 Among injector prisoners, sexual risk 
practices were also important determinants of hepatitis B infection status.   
5.6 Screening, treatment and vaccination
Screening 
There are 10 genito-urinary medical units in hospitals throughout 
Ireland. Hepatitis B is classified as a sexually transmitted infection and 
may be diagnosed at these units. Because of the link between hepatitis 
B and injecting drug use, hepatitis B screening is also conducted at drug 
treatment services and through the prison health service.  Grogan et al.11 
estimated that 68% of clients attending drug treatment services in the 
HSE South Western Area had been tested for antibodies to hepatitis B 
core antigen and 84% had been tested for hepatitis B surface antigen by 
December 2001.  
Treatment 
Treatment for acute hepatitis B is mainly supportive. Interferon therapy 
has been used for the treatment of chronic hepatitis B. In 1990, Perillo 
et al.44 reported that, of those treated with interferon alpha 2b for 16 
weeks, 36% no longer had hepatitis e-antigen and hepatitis B viral DNA 
detected in their serum, compared to 7% of untreated controls. In the 
mid-nineties, Niederau et al.45 followed up a prospective cohort of 103 
treated individuals and 53 untreated individuals. The authors reported 
that hepatitis e antigen and hepatitis B viral DNA were no longer detected 
in 52% of those treated with interferon alpha, compared to 16% of 
the untreated cohort. Almost 10% of the treated group were no longer 
carriers of the hepatitis B virus, whereas none of the untreated group had 
lost their carrier status. Interferon is useful only for patients who have 
no immunodeficiencies. The National Institute for Health and Clinical 
Excellence (NICE) is developing clinical guidance notes on the treatment 
of chronic hepatitis B.  The use of drugs such as adefovir, dipivoxil and 
pegylated interferon alpha-2a for the treatment of chronic hepatitis B will 
be covered in these guidance notes.46
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Vaccination 
In Ireland, hepatitis B vaccine is recommended for several high-risk groups; 
prisoners and injecting drug users are two of the high-risk groups named 
in the Immunisation guidelines for Ireland 2002.43 The safety, effectiveness 
and regimen of the vaccination programme are well established. There 
are several accelerated vaccine schedules. The current vaccine schedule, 
Day 0, Day 7, Day 21, with a booster at 12 months, results in 65% sero-
protection at Day 28 and 99% protection at 13 months.47 The effectiveness 
of hepatitis B vaccination among injecting drug users may be lower than 
that among the general population because of the generally poorer health 
status among this group, including HIV co-infection.48  This does not mean 
that hepatitis B vaccine should not be administered to injecting drug users 
but that serum should be tested to ensure that the recipient has developed 
an appropriate immune response to the vaccine. 
In Ireland, hepatitis B vaccine is free to all injecting drug users attending 
drug treatment centres, but is not necessarily free to all injecting drug 
users attending general practice. The vaccine has become easily available 
at drug treatment centres but is more difficult to access at general practice. 
In general, doctors caring for injecting drug users in the general practice 
setting must order an individual dose of vaccine for each injecting drug 
user they intend to vaccinate. Those injectors without a medical card must 
pay for the vaccine. This reduces the scope for opportunistic vaccination, 
which is considered an important strategy to achieve a high level of 
immunisation in a vulnerable group.
The coverage of hepatitis B vaccination for injecting drug users is not 
monitored on a continuous basis; the coverage estimates presented in this 
section were taken from ad hoc studies in particular settings such as needle 
and syringe exchange, treatment centre, prison and general practice (Table 6). 
Fitzgerald et al.20 reported that only 18% of clients attending five 
methadone clinics in the Dublin area in 1997 had one or more doses of 
hepatitis B vaccine documented in their medical record; only 15% had 
completed three doses of the vaccine.  
5 Hepatitis B
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A study of 1,337 new clients attending the Health Promotion Unit at 
Merchants Quay in Dublin between 1 May 1997 and 31 October 1998 
found that only 19% (of 1,308) clients reported having had one or more 
doses of hepatitis B vaccine.49 The study did not ascertain how many doses 
of hepatitis B vaccine these clients had received. A higher proportion of 
male clients (22%) had received one or more doses of the vaccine than 
had their female counterparts (11%). Furthermore, a higher proportion 
of clients (30%) who had ever been in prison had received one or more 
doses of the vaccine than had the proportion that had never been in prison 
(8%). Since men are more likely to be imprisoned than women, it is likely 
that most of the clients attending the Health Promotion Unit at Merchants 
Quay had received their hepatitis B vaccination in prison. Of the 1,337 
new clients, 370 completed a follow-up questionnaire three months after 
their initial contact with the Unit. The overall uptake of hepatitis B vaccine 
increased by 2% over the three-month period, from 16% to 18%. 
It is Department of Justice, Equality and Law Reform policy that all 
prisoners should be offered hepatitis B vaccine. In 1998 and 1999, two 
studies estimated self-reported uptake and coverage of hepatitis B vaccine 
among prisoners.31, 32  In 1998, 29% (302/1045) of respondents in the 
prison inmates survey reported completing three doses of hepatitis B 
vaccine, compared with 10% (55/554) in the prison entrants survey in 
1999. The proportion that had completed three doses of the vaccine in 
the entrants survey increased to 13% (50/373) when those individuals 
who had never spent time in prison were excluded. In the prison inmates 
survey, an additional 19% (199/1045) had completed one or two doses 
of the vaccine, compared to 12% (66/554) in the prison entrants survey. 
In both surveys, uptake rates were higher among those who had spent 
more than three of the previous 10 years in prison. For example, in the 
entrants survey, only 4% (7/180) of respondents who had never spent 
time in prison had had one or more doses of hepatitis B vaccine, while 
23% (52/228) of those who had spent between one day and three years 
in prison had accessed one or more doses, and 61% (52/85) of those who 
had spent more than three of the previous 10 years in prison had accessed 
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one or more doses of vaccine. In both prison surveys, uptake rates were 
higher among injecting drug users. For example, in the inmates survey a 
significantly higher proportion of injecting drug users (63%, 298/476) than 
non-injectors (36%, 201/561) had had one or more doses of hepatitis B 
vaccine. 
It is important to note that, in both surveys, of the respondents who 
had previously spent time in prison, the vast majority who had accessed 
hepatitis B vaccine had done so while in prison: 91% (443/488) of 
respondents in the inmates survey and 82% (89/108) in the entrants 
survey. 
In both prison surveys, a higher proportion of those who tested positive 
for antibodies to hepatitis B core antigen had one or more doses of 
hepatitis B vaccine than had antibody-negative respondents. In the entrants 
survey, 36% (13/36) of antibody-positive respondents, compared to only 
20% (105/518) of antibody-negative respondents, had had one or more 
doses of vaccine. This indicates the need to administer vaccination as 
early as possible (at needle- and syringe-exchanges facilities, low-threshold 
services and treatment centres).  Only a minority of needle exchanges 
and low-threshold services have medical personnel on hand to administer 
vaccinations; the limited provision of this important intervention for high-
risk groups needs to be addressed.  
In 2001 Cullen et al.50 implemented a pilot project to improve the care of 
injecting drug users attending general practice who were at risk of hepatitis 
C. Prior to implementing the project, the authors did a baseline assessment 
that included hepatitis B vaccine coverage. Of the 196 respondents, only 
16% had documented evidence of having received three doses of hepatitis 
B vaccine within a seven-month period. Self-reported hepatitis B vaccine 
coverage was higher than documented coverage: 23% had three doses, 
11% had two doses and 14% had received one dose. At the end of the 
study in 2002, the completed vaccination rate in the intervention group 
was higher (36%) than that in the control group (21%). 
5 Hepatitis B
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In 2001, Grogan et al.11 estimated that 81% of 316 clients in the HSE 
South Western Area for whom the hepatitis B vaccine was indicated had 
commenced a course of the vaccine and 177 (56%) had completed at least 
three doses. 
Between 2002 and 2003, O’Sullivan23 estimated that 86% of those 
attending the Drug Treatment Centre Board for whom the vaccine was 
indicated tested positive for anti-HBs, which indicated in these cases a 
vaccine-induced immunity.  
5.7 Policy and strategy
The issue of hepatitis B infection and the association between injecting 
drug use and high-risk sexual behaviour are addressed in the sexual health 
strategy produced by the HSE Eastern Region.51 The Steering Committee 
for this strategy recommended three levels of care to promote sexual health 
among the population.  The primary level of care will promote informed 
decision-making and screening for sexually transmitted diseases (including 
hepatitis B); hepatitis B vaccine will be promoted in primary care services.  
The second level of care will be delivered by specialist general practitioners 
who will provide surgical methods of contraception and comprehensive 
primary care services for particular vulnerable groups, such as injecting 
drug users. The third level of care will provide consultant-led specialist 
genito-urinary medical services.    
5.8 Conclusions
All cases of hepatitis B in Ireland are notified to the directors of public 
health in the Health Service Executive (HSE). Up to the end of 2004, the 
notification system did not categorise cases by risk group or differentiate 
between new and previously diagnosed cases. In 2005 an extended 
surveillance system for hepatitis B was introduced and information 
on newly diagnosed cases of hepatitis B, by risk factor status, will be 
available at the end of 2006.  Just under one-fifth of injecting drug users 
in treatment have ever been infected with hepatitis B and approximately 
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2% are chronic cases. Age, injecting practices and sexual practices are 
linked to hepatitis B status.  The uptake and completion rates of hepatitis 
B vaccination among injecting drug users are much higher in the HSE 
South Western Area (56%) and in Drug Treatment Centre Board (86%) 
cohorts for the period 2001 to 2003 than those reported in prisoners 
or at general practice in Ireland between 1998 and 2001. This possibly 
indicates an increase in hepatitis B vaccine coverage in recent years. There 
are no published data on the coverage of hepatitis B vaccine outside the 
HSE Eastern Region.  It is important to ensure that hepatitis B vaccine is 
administered as early as possible in a drug user’s career; therefore, needle 
exchange and low-threshold methadone services require facilities to deliver 
this intervention on a daily basis.
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6  Hepatitis C
6.1  Introduction
This section presents an overview of published research on hepatitis C 
associated with injecting drug use. The background, incidence, prevalence, 
risk factors, treatment and prevention are presented. With the exception of 
background and treatment, the review of issues is based substantially on 
the Irish literature. 
6.2 Background
In the 1970s a new type of hepatitis was identified and classified as non-A 
non-B hepatitis. Hepatitis C virus was identified in 1988 and the first test 
to identify the virus was developed in 1991. This virus is a single-stranded 
RNA virus belonging to the Flaviviridae family. The incubation period for 
hepatitis C ranges between two weeks and six months. There is evidence 
that the virus causes liver disease and may affect other organs such as the 
skin, thyroid and kidneys. Among the general population, evidence available 
to date indicates that 20% to 25% of individuals infected with hepatitis 
C clear the virus spontaneously. There are six genotypes for hepatitis C; 
treatment outcomes are dependent on genotype and other factors. 
The main route of transmission is parenteral (through infected blood 
and blood products and contaminated needles and syringes), although 
there is evidence of vertical transmission (in utero or during childbirth) in 
approximately 5% of infected women. There is evidence that individuals 
who received infected blood and blood products have been infected. 
For example, almost 100% of haemophilia patients were infected prior 
to blood donor screening for hepatitis C. Injecting drug users are a 
high-risk group for hepatitis C; in a small number of reported cases the 
infection was acquired through tattooing and needle-stick injuries. Sexual 
transmission occurs rarely and seems to be associated with HIV co-
infection and to be more common in those with multiple sexual partners. 
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Keating and colleagues52 estimated the proportion of hepatitis C antibody-
positive individuals with each genotype in a cohort of injecting drug users, 
and then estimated the proportion that spontaneously cleared the virus, 
using a PCR test. The PCR test assesses whether the virus is still detectable 
in the blood and will show if a person has an ongoing infection. The 
study followed the progress of a sample of hepatitis C antibody-positive 
individuals attending five drug treatment centres in Dublin. None of this 
cohort had tested positive for hepatitis B or HIV. Of the 496 hepatitis C 
antibody-positive participants in the sample, 191 (38.5%) were shown 
to be HCV RNA negative when re-tested, indicating that they had 
spontaneously cleared the virus. A higher proportion of women (47.4%) 
than men (34.5%), p <0.01, cleared the virus spontaneously.  A higher 
proportion of those with a history of jaundice (12.0%) cleared the virus 
spontaneously than did those that reported no history of jaundice (7.9%), 
p <0.01. Neither age nor duration of injecting drug use were associated 
with spontaneous hepatitis C virus clearance. The rate of spontaneous viral 
clearance was higher than previously reported. Of the 299 PCR-positive 
samples that had their genotype determined, genotype 1 and genotype 3 
were the most common (Table 7). 
Table 7   Number of PCR-positive samples, by genotype, of selected 
hepatitis C antibody-positive injecting drug users attending five drug 
treatment centres in Dublin
Genotype Number (%)  
 Total = 299
1 146 (48.8)
2 6 (2.0)
3 145 (48.5)
4 2 (0.7)
5 0   (0.0)
6 0 (0.0)
Source: Keating et al.52
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6.3 Newly diagnosed hepatitis C cases
Hepatitis C occurs mainly in two populations in Ireland: cohorts of individuals 
who became infected through infected blood and blood products, and 
injecting drug users. Under the reporting regulations in force up to the end of 
2003, hepatitis C could be notified as ‘viral hepatitis, type unspecified’.  It was 
not a notifiable disease in its own right and there was no national surveillance 
system to monitor the incidence of this infection among the population. 
Among the changes to infectious disease legislation introduced on 1 January 
2004 was the inclusion of hepatitis C in the list of notifiable diseases.1 
There were 1,154 cases of hepatitis C reported in 2004, compared to 85 
cases of ‘viral hepatitis, type unspecified’ in 2003.40 In 2004, 954 cases 
were notified by the HSE Eastern Region and 200 cases were notified by 
the HSE areas outside the Eastern Region.  Each of the seven HSE areas 
outside the Eastern Region reported cases of hepatitis C, ranging from 
five in the HSE North Western Area to 45 in the HSE Southern Area. 
Three out of every five hepatitis C cases reported were male.  Of the 1,132 
cases for whom age and gender were known, 83% were aged between 
20 and 44 years. Of the 14,390 persons diagnosed with hepatitis C viral 
antibodies by the end of 2002 in Scotland (which has similar patterns of 
injecting drug use to Ireland), 90% of those for whom at least one risk 
factor was known had injected drugs.53
Between 1992 and 1998, Smyth et al.13 estimated the incidence of hepatitis 
C among 100 injecting drug users attending treatment in Dublin who had 
an initial negative test and a repeat test within nine months. The authors 
reported that the incidence of hepatitis C was 66 per 100 person years (95% 
CI, 51 to 84); this is higher than estimates reported among injecting drug 
users living in other countries (16 to 38 per 100 person years).  Between 2001 
and 2002, Grogan et al.11 reported that the incidence of hepatitis C was 24.5 
per 100 person years (95% CI, 12.2 to 43.8) among opiate users (including 
some non-injectors) in the HSE South Western Area; this is lower than that 
reported by Smyth et al. but comparisons are difficult as it is not easy to 
ascertain the proportion of non-injectors in Grogan’s sample.  According to 
6 Hepatitis C
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unpublished data from the National Drug Treatment Reporting System, 73% 
of treated opiate users living in the HSE South Western Area between 2001 
and 2002 were injectors.  
6.4 Prevalence
Blood donors and antenatal women, who are routinely tested for blood-
borne viral infections, may be used as proxy groups for the general 
population.
There is no national prevalence estimate available for hepatitis C in the 
general population. The prevalence of hepatitis C among new blood 
donors living in Dublin is low, at 28 per 100,000 (0.03%) between 1996 
and 2001 (E Lawlor, personal communication, 2003). The prevalence 
of HIV and hepatitis B among the antenatal population was three times 
that among new blood donors living in Dublin. There is no reason not to 
believe that a similar risk ratio between new blood donors and antenatal 
women exists for hepatitis C.  
A number of studies carried out in the past 10 years have estimated the 
prevalence of hepatitis C among injecting drug users. Prevalence estimates 
among injecting drug users attending community-based drug services range 
from 52% to 84% (Table 8). Hepatitis C is endemic among injectors in 
prison; the prevalence of hepatitis C antibodies among injecting inmates 
and entrants was 81% and 72% respectively (Table 8). 
In Ireland there are no published prevalence estimates of hepatitis C 
among injecting drug users attending needle exchange or among those not 
attending drug services. However, the prevalence of hepatitis C is over 
2,000 times higher among injectors attending drug treatment services 
than among new blood donors living in Dublin, indicating the excess risk 
among injecting drug users. If it is assumed that the prevalence among the 
antenatal population is three times that among new blood donors living in 
Dublin, then the antenatal population prevalence would be 0.1%, which is 
about 700 times lower than that among injecting drug users.
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6.5 Risk factors
Healy et al.54 examined risk factors for infection among 296 women 
who attended Irish antenatal clinics and tested positive for hepatitis C 
between 1994 and 1999. The authors reported that 82% were infected 
through injecting drug use, 8% through heterosexual contact and 7% via 
blood and blood products. Allwright et al.21 and Long et al.22 reported 
that injecting drug use was the most serious risk factor for hepatitis C in 
Irish prisoners. Allwright et al.21 and Smyth et al.13 reported that spending 
time in prison was associated with an increased risk of testing positive for 
hepatitis C antibodies (Table 9).  Length of time injecting appears to be 
strongly associated with contracting the infection (Table 9). For example, 
among drug users attending Trinity Court Drug Treatment Centre the 
prevalence of hepatitis C was 52% among those injecting for less than 
25 months, compared to 84% among those injecting for 25 months or 
more.18, 55 Also, the prevalence of hepatitis C was 65% among prison 
inmates injecting for less than 36 months, compared to 85% among those 
injecting for 36 months or more.21 Practices such as injecting frequency 
and sharing needles were also associated with testing positive for hepatitis 
C (Table 9). Smyth et al.56 examined the contribution to infection with 
hepatitis C of unsafe injecting practices and the social context of injecting 
in Dublin. In relation to the social context, individuals who injected in the 
home of another injecting drug user were almost five times more likely to 
test positive for hepatitis C than those who injected in their own home or 
in another place. Those individuals who injected in the company of close 
friends and family members were around three times more likely to test 
positive for hepatitis C than those who injected with acquaintances.  
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6.6 Knowledge, beliefs and behaviours
Smyth et al.58 investigated the extent of knowledge about hepatitis C 
among injecting drug users attending drug services and found that over 
three-quarters of the respondents knew the main routes for transmission 
(i.e. sharing injecting equipment, sex, blood transfusion and vertical). The 
proportion responding correctly was lower when asked about activities 
with no recognised risk: only 44% recognised all three `safe’ activities (i.e. 
injecting without sharing, smoking rather than injecting, and kissing). Over 
one-third incorrectly believed that one could contract hepatitis C virus 
even while injecting safely. This misinformation is a major barrier to the 
observation of safe injecting practices by drug users. 
Dillon59 examined drug use among Irish prisoners; respondents reported 
a general lack of knowledge about HIV and hepatitis. Long et al.60 
reported that injector-prisoners had satisfactory knowledge about 
transmission, while non-injectors revealed a number of misconceptions 
(such as transmission via toilets, cups or glasses). In the study by Long 
and colleagues60 a number of respondents reported that they sought 
information on blood-borne viruses from leaflets and books, which is 
consistent with Klee’s61 identification of sources of information about HIV 
accessed by injecting drug users in the late eighties. Klee also noted that 
injecting drug users were interested in information about their habits, and 
that this information provided them with a sense of control.
Long et al.62 explored how prisoners (both injectors and non-injectors) 
dealt with the possibility of either contracting or testing positive for 
hepatitis C. Two dominant themes emerged: denial and fear. Injector-
respondents dealt with the possibility by living in the moment; distancing 
its effects in time; generalising the condition to all injectors; and comparing 
its consequences to those of HIV. This process allowed them to continue 
injecting without acknowledging the risk to themselves. Most injector-
respondents believed that hepatitis C was common among those who 
injected drugs and that, to date, its consequences had not been serious. 
The fears expressed by injectors and non-injectors were in the main well 
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founded. Fear of contracting a blood-borne virus, or the actual receipt 
of a diagnosis of viral infection, deterred a number of heroin users from 
starting or continuing to inject heroin. Similar numbers of injector and 
non-injector respondents reported that they feared contracting blood-borne 
viruses while in prison. 
Cullen et al.63 examined the experience of heroin users attending 
general practice with respect to risk practices for hepatitis C. The study 
questionnaire had a mix of closed and open questions. At the time of the 
study, 38 former or current heroin users were registered with the practice. 
Of these, 25 (66%) agreed to be interviewed. Those interviewed were more 
likely to be female and older than the other heroin users attending the 
practice.  At the time of the study, 23 of the 25 participants were receiving 
methadone maintenance (14 at the practice and nine at specialised drug 
treatment centres).  Twenty-two participants said that they had tested 
positive for hepatitis C, of whom 15 had consumed alcohol in the week 
prior to the study.  Nine had consumed more than the recommended 
amount for their gender.  The respondents identified ‘not sharing needles’, 
‘adopting safe sexual practices’ and ‘not using drugs’ as ways to avoid 
hepatitis C transmission.  Respondents who reduced their alcohol intake 
did so because they were concerned about their health, while those who 
increased their alcohol intake did so to substitute for heroin. 
6.7 Burden of disease
Brennan et al.64 ascertained that between 1999 and 2001 the Hospital 
In-Patient Enquiry (HIPE) scheme recorded 6,085 discharges from acute 
hospitals with hepatitis C as a primary or secondary diagnosis. This 
scheme is an event-based register so cases may be represented more than 
once.  Of the 6,085 hepatitis C cases: 
 • 18% had hepatitis C as a primary diagnosis 
 • 57% had a diagnosis of chronic hepatitis C
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 • 21% had a diagnosis of problem opiate use 
 • 7% had a diagnosis of hepatitis B
 • 24% had a diagnosis of HIV/AIDS 
 • 11% had a diagnosis of chronic liver disease or sequelae
 • 0.4% had a diagnosis of liver cancer.
These data suggest the existence of a combination of blood-borne viral 
infections in some individuals, and indicate the damage that hepatitis C 
can do to the liver.  It is important to note that injecting drug user status 
was not systematically recorded for all of these cases.  
Kavanagh et al.65 investigated the outcome of end-stage liver disease in 
injecting drug users infected with hepatitis C in Ireland by means of a  
cross-sectional survey of attendees at a HSE East Coast Area drug 
treatment clinic. Of 94 patients studied, 63 were male, 70 were hepatitis 
C antibody positive and 39 were PCR positive. Twenty-six had genotype 
1 and eleven had genotype 2 or genotype 3. Most displayed factors 
associated with a poor prognosis: 72% were male, 83% were problem 
drinkers and 87% had abnormal liver blood tests. Using published data, 
the authors extrapolated that there were over 1,214 cases of cirrhosis 
nationally as a result of hepatitis C associated with injecting drug use, 
leading to approximately 35, 60 and 50 cases of hepatocellular carcinoma, 
hepatic decompensation and liver-related death respectively per annum. 
A high prevalence of hepatitis C infection in injecting drug users, 
compounded by a high frequency of poor prognostic co-factors, means 
that significant morbidity is experienced by this group.
6.8 Mortality
It is difficult to ascertain the annual number of deaths in Ireland as a result 
of hepatitis C because the ICD 9 coding scheme does not have a specific 
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code for hepatitis C cases.  Brennan and colleagues64 requested the Central 
Statistics Office to select cases where the primary cause of death was 
hepatitis ICD 9, category 070.4, 070.5 or 070.6.  This allowed the authors 
to calculate the number of deaths with a primary diagnosis of hepatitis 
C using the diagnoses hepatitis ‘other specified’ or ‘unspecified’ as proxy 
diagnoses. Using these proxy codes, the authors estimated that 50 persons 
died as a result of hepatitis C between 1995 and 2002.  Up to 2001, the 
numbers for each year fluctuated between three and seven cases, with a 
rise to 15 cases in 2003.  The main risk factors for hepatitis C cannot be 
identified accurately on the basis of mortality data held by the Central 
Statistics Office; therefore, it is not possible to know how many of these 
deaths can be attributed to injecting drug use.  This suggests the need for 
a special register to record the contribution of hepatitis C to premature 
death among injecting drug users. 
6.9 Treatment and prevention
The hepatitis C virus has six major genotypes and several closely related 
sub-types. This has made it difficult to develop both effective treatment 
and vaccination. Genotype 1 and genotype 3 are the most common in 
Ireland.66, 52 Treatment is more successful for genotype 3 than for genotype 
1. Hepatitis C is a chronic illness that often has no overt symptoms, but 
this population is likely to experience significant morbidity in the future.
Manns et al.67 conducted a randomised control trial of treatment options 
for chronic hepatitis C. The authors reported that, compared with standard 
interferon alpha and ribavirin, peginterferon alpha-2b and ribavirin 
achieved a higher sustained viral response rate (undetectable hepatitis C 
virus RNA in serum) at 24 weeks following treatment.  The sustained viral 
response rate was significantly higher in the higher-dose peginterferon 
group (274/511, 54%) than in either the lower-dose peginterferon group 
(244/514, 47%) or the interferon group (235/505, 47%). Among patients 
with HCV genotype 1 infection, the corresponding sustained viral response 
rates were 42% (145/348), 34% (118/349), and 33% (114/343). The rate 
for patients with genotype 2 and genotype 3 infections was about 80% 
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for all treatment groups. This combination therapy is recommended as the 
most appropriate treatment for hepatitis C and is the current treatment 
regime in Ireland. The treatment offered is peginterferon by subcutaneous 
injection once weekly and ribavirin taken daily by mouth. 
There are seven specialist hepatology centres for adults and one for 
children in Ireland:
 • St James’s Hospital  (three consultants)
 • St Vincent’s Hospital (two consultants)
 • Mater Misericordiae Hospital (one consultant)
 • Beaumont Hospital (one consultant)
 • University College Hospital, Galway (one consultant) 
 • University College Hospital, Cork (one consultant) 
 • St Luke’s Hospital Kilkenny (one consultant)
 • Our Lady’s Hospital for Sick Children (one consultant). 
There are a number of nurse specialists and counsellors supporting patients 
at these services. There is a liaison medical officer for hepatitis C based at 
the Drug Treatment Centre Board at Trinity Court in Dublin.
Dr Keating of the Drug Treatment Centre Board updated the booklet 
Hepatitis C: A Guide for Drug Users and their Families in 2003.68 The 
information in this booklet is essential for drug users, particularly for 
injecting drug users at risk of or diagnosed with hepatitis C. It is also a 
useful tool for doctors, nurses and counsellors who educate drug users 
about hepatitis C. The booklet is laid out in a question and answer 
format that addresses issues commonly raised by patients and their 
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families. It provides updated information on the condition itself and 
on its treatment. The booklet also provides transparent information on 
the criteria for entering treatment and the side effects of treatment. It 
is generally recommended that treatment be offered to those who are 
both drug and alcohol free for six months, or stable on methadone and 
alcohol free for the same duration. The individual’s living status is also a 
consideration and, ideally, a prospective patient should be living in stable 
accommodation. The author clearly states that therapy is not offered to 
those actively abusing drugs or alcohol. 
The routine assessment procedures for hepatitis C are as follows: initially, 
the individual has a blood test to determine whether s/he has antibodies 
to the hepatitis C virus. If such antibodies are detected, the individual will 
have a PCR (polymerase chain reaction) test to determine whether the 
virus is still detectable in the blood; a positive PCR test indicates active 
chronic hepatitis C. The genotype will also be determined. Liver enzymes 
in blood will be measured; high enzyme levels indicate damage to the liver, 
though low levels do not necessarily indicate there is no liver damage. If 
PCR-positive, the hepatologist might recommend an ultrasound of the liver 
or a liver biopsy, or both.68
In 1996 and 1997, Smyth et al.69 examined uptake of hepatitis C screening 
and assessment among injecting drug users in the eastern region of Ireland. 
They found that of the 119 clients offered a test for hepatitis C, only 48 
(40%) proceeded to have such a test. Of the 48 who had the test, 20 tested 
positive for hepatitis C, of whom only five were seen by a consultant 
hepatologist. Of the 119 clients who started the hepatitis screening and 
assessment process, only 21 completed it. This indicated poor uptake of 
hepatitis C screening and follow-up. McMahon et al.70 followed up 43 of 
98 injecting drug users who dropped out of treatment (for problem drug 
use) to determine if they had subsequently completed an assessment of 
their hepatitis C status elsewhere. The authors reported that only seven 
(16%) had completed the assessment process at another service over 
a 26-month period. Overall, the findings of these studies demonstrate 
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that among injecting drug users there is very low uptake of hepatitis C 
screening and assessment. In a more recent study, Grogan et al.11 estimated 
that 88% of clients attending drug treatment services in the HSE South 
Western Area had been tested for hepatitis C antibodies by December 
2001. This study did not estimate the uptake of assessment opportunities 
by those testing positive for antibodies to the hepatitis C virus.  
Both Dillon59 and Long et al.60 reported low access to treatment for 
hepatitis C in Irish prisons. 
In 2002, Cullen et al.50 examined uptake of care (including treatment) for 
hepatitis C by injecting drug users living in the HSE Eastern Region. Each 
injector had tested positive for hepatitis C and was receiving methadone 
therapy from a general practitioner. The authors reported that, of the 
104 clients who were hepatitis C positive, 43% had discussed referral to 
a consultant hepatologist with their general practitioner, 32% had the 
referral process initiated by their general practitioner, 25% attended the 
specialist clinic, 13% had a liver biopsy and 3% commenced treatment for 
hepatitis C. 
Cullen et al.63 examined the experience of heroin users attending general 
practice with respect to investigation of and treatment for hepatitis C 
through in-depth interviews.  Twenty-two participants said that they had 
tested positive for hepatitis C. Eight respondents reported neither drinking 
excessively nor using heroin in the previous six months and were therefore 
suitable for investigation. Only four of the eight suitable clients were 
referred for further investigations and one had commenced treatment. 
Some respondents had a negative perception of liver biopsy, though those 
who had undergone this investigation reported that the procedure was 
not as difficult to tolerate as expected.  Many respondents had negative 
perceptions of antiviral treatment.  The experience of care by medical 
and nursing personnel at secondary treatment services was mixed, with 
some having very positive experiences while others reported that the 
service providers were impersonal and withheld information.  The authors 
concluded that there were a number of barriers to hepatitis C treatment 
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for injecting drug users and that these needed to be addressed so as to 
encourage uptake of treatment.  
Cullen led the Dublin Area Hepatitis C Initiative Group who developed 
consensus guidelines on the management of hepatitis C in general practices 
in the Eastern Region.71 The guidelines were produced in five stages: 
identification of key stakeholders; development of evidence-based draft 
guidelines; discussion of content; reaching consensus using the Delphi 
method; and review of guidelines by a sample of general practitioners. The 
guidelines are presented in a logical format, by key aspects of care, and 
include:  
 •  General aspects of care, covering the means of transmission and 
actions to protect the client and others
 •  Prevention of, and care for clients with, other blood-borne or other 
hepatotoxic viral infections, including hepatitis A and B vaccination 
 •  Screening for and presentation of hepatitis C test results, which 
include pre-test counselling, post-test counselling and explaining 
hepatitis results 
 •  Initial management of patients infected with hepatitis C, which 
includes information on means of transmission, alcohol and drug 
use, nutrition, vaccination and weight reduction (where necessary)
 •  Subsequent management of patients with hepatitis C, which 
includes referral to a hepatology service, criteria for treatment and 
information required by the hepatology service.
The guidelines introduced flexibility around the period of time hepatitis C 
positive opiate users are required to be stable on methadone or opiate free, 
and provided clear referral processes and procedures. The guidelines were 
implemented in selected general practices with the assistance of a hepatitis 
C nurse specialist over a six-month period. The researchers randomly 
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allocated clients who had tested positive for hepatitis C to either an 
intervention or a control group. For the purposes of the results presented 
in this document, the numbers in the intervention and control groups were 
72 and 35 respectively.50  At the end of the six-month intervention period, 
the authors reported that increased numbers of clients had had referral to a 
specialist discussed, had had the referral process initiated and had attended 
the specialist clinic (Figure 4). Among the intervention group, only 25% 
had had a liver biopsy and 7% had commenced treatment for hepatitis C; 
these low uptake rates may be a reflection of the short time period over 
which the data were collected. The follow-up phase indicated that injecting 
drug users were interested in assessment for hepatitis C provided that 
clinical staff at general practice level actively supported them in seeking 
assessment.
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Figure 4   Comparison between an intervention and a control population 
in terms of selected indicators relating to the management of hepatitis C 
in a general practice setting 
Adapted from Cullen et al.50
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In Ireland, the only published data on compliance with treatment for 
hepatitis C is a small on-site hepatitis C treatment pilot study that was 
commenced at the Drug Treatment Centre Board, in liaison with the 
infectious diseases unit in St James’s Hospital. On 10 December 2003 at 
the Drug Treatment Centre Board, Dr Keating72 presented the results of 
this pilot study that examined the potential for ‘treating hepatitis C at 
the same location at which clients receive their methadone with a view 
to retaining the patients in treatment’.  Dr Keating emphasised that any 
centre providing hepatitis C treatment required referral pathways to 
specialist hepatology and psychiatric care. Access to psychiatric care is 
required because many of those with hepatitis C may have a history of 
psychiatric illness, and because depression is a side effect of interferon (one 
of the two drugs used to treat hepatitis C). The specialist hepatology care 
included the services of a nurse-specialist and a medical officer. In May 
2003, nine patients commenced treatment and, at the time of presenting, 
only one had defaulted. Dr Keating concluded that providing hepatitis 
C treatment at drug treatment centres was ideal as it improved patient 
compliance and permitted a rapid response to incidences of illicit drug 
use and psychiatric illness. Delivery of hepatitis C treatment alongside 
methadone treatment was also more convenient for clients. He also said 
that increased treatment costs at the drug treatment centres could be 
offset by reduced costs at hospital level. It should be noted that the study 
methods would have been strengthened by the inclusion of larger numbers 
of subjects and the recruitment of a comparison group receiving treatment 
through a specialist centre. The complete presentation can be accessed on 
line (www.addictionireland.ie). 
6.10 Policy and strategy
At present there is no policy or strategy that provides guidance on the 
management of hepatitis C among injecting drug users.  
The findings of a consultation event held in June 2004 to assess the health 
and social care requirements for those with or at risk of acquiring hepatitis 
C were released in December 2004.73  Over 70 people attended the event, 
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among them service planners, health and social care professionals and 
service users. The method used in the consultative process was ‘open 
space technology’.  ‘Open space’ is a qualitative method used to enable 
a large and diverse group of people to explore complicated issues in a 
limited time by presenting participants with central themes. Organic and 
self-organising, the participants set a detailed agenda and subsequently 
facilitate qualitative discussion at impromptu workshops. The contents 
of the discussions are simultaneously documented. The central themes, 
presented in the invitation to this event, were: ‘What are the significant 
issues in formulating a region-wide policy on hepatitis C?’ and ‘What are 
the optimum approaches to these issues?’
With respect to the first of the central themes, participants identified 
16 significant issues on the morning of the event and a workshop was 
organised for each issue. A small group discussion took place on each topic 
and a workshop facilitator recorded the issues raised during the discussion. 
These data were subsequently analysed using qualitative methods. 
Four common themes emerged from the 16 workshops:
 • Health promotion 
   There is a need to develop a set of consistent messages on modes of 
transmission, pathways to treatment and success of treatment, with 
such messages delivered through a variety of media. 
 • Role of the media 
   There is a need to ensure that the mass media provides accurate 
information to the general public and high-risk groups. It was 
suggested that the media use an approach that allays fears and 
reduces the stigma associated with the infection. 
 • Service provision 
   It was noted that access to and availability of services to prevent 
or treat hepatitis C should not be associated with mode of 
transmission. There is a need for equivalence of care between several 
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groups; for example, between those who acquired their infection 
through blood products and injecting drug users; between those who 
live in Dublin and those living outside Dublin; and between those in 
prison and those in the community. The information about, criteria 
for and pathways to treatment should be transparent and easily 
accessed. Expansion of nursing and psychology services to support 
those testing positive for hepatitis C is required. 
 • Research, policy and planning 
   In general, the participants emphasised the importance of an 
extended surveillance system to ascertain the extent of the problem 
but stressed that such a system must protect the identity of the 
individual. Participants also wanted research to develop best-practice 
protocols (including medical and complementary therapies) to 
manage this infection. 
 In the afternoon session, the process was repeated to explore optimum 
approaches to the themes identified in the morning. Eight actions were 
identified and a workshop was organised to deal with each action. A 
number of common themes emerged from the second set of workshops:
 • Peer support and prevention  
   The importance of using peer groups in planning and developing 
prevention, harm reduction and treatment interventions was 
stressed. Peer-group insight and experience were considered very 
useful in ensuring that new approaches would be appropriate. It was 
also suggested that indicators be developed to monitor and evaluate 
prevention and harm reduction interventions. 
 • Education and training 
   The actions suggested were in line with the health promotion actions 
identified in the morning session. 
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 • Liaison, key workers, co-ordination and collaboration 
   A number of suggestions were made, including appointment of 
key workers (such as liaison nurses); development of transparent 
communication policies and procedures; improvement in access to 
services through multi-agency collaboration; and introduction of a 
monitoring group to ensure client-centred services.  
  • Accessing services 
   Developments to make services more accessible and user-friendly 
were identified as a priority. 
 • Psychological and complementary therapies 
   Respondents thought that psychological support and complementary 
therapies, in conjunction with medication, would be very beneficial 
to a client’s quality of life. 
The event represented an ongoing collaboration between two groups – the 
Hepatitis C Scientific Advisory Subgroup of the Blood Borne Virus Forum (a 
group of health and social care professionals with an interest in hepatitis C 
and related issues) and the HSE Eastern Region. At the launch of this report 
in December 2004, the ERHA area (now the HSE Eastern Region) presented 
its response to the findings and its plans for the future.  The findings of 
the open space event are being used to help inform the draft HSE Eastern 
Region’s hepatitis C strategy.  It was indicated that a group convened to 
formulate a regional strategy on hepatitis C intends to audit the health 
services available to those with hepatitis C and to provide information on 
service availability and identify models of best practice both nationally and 
internationally.  This strategy will be published in 2006.  
As mentioned in the HIV section of this Overview, the Irish Prison 
Service published its drugs policy and strategy in May 2006.36 The drug 
treatment approaches proposed in the strategy document will be adapted 
for prisoners with special needs, including drug users with mental health 
problems or hepatitis C.
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6.11 Conclusions
Among the changes to infectious disease legislation introduced on  
1 January 2004 was the inclusion of hepatitis C in the list of notifiable 
diseases. All cases of hepatitis C in Ireland are notified to the directors 
of public health in the Health Service Executive (HSE). Newly diagnosed 
cases of hepatitis C are not reported by risk factor status.  Around 
70% of injecting drug users attending drug treatment tested positive for 
antibodies to the hepatitis C virus. Injecting practices and prison history 
are associated with hepatitis C status. There are seven specialist hepatology 
centres for adults and one for children in Ireland. A number of studies 
demonstrated low rates of access to and uptake of treatment for hepatitis 
C among injecting drug users. Two small studies demonstrated that a 
decentralised approach to initial assessment at general practice level and 
hepatitis C treatment at drug treatment centres achieved higher uptake and 
compliance rates than the current centralised approach.  The publication of 
the HSE Eastern Region’s hepatitis C strategy is awaited.  
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7 Blood-borne viral co-infection
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7  Blood-borne viral co-infection
The findings from international literature74 indicate that infection with 
hepatitis C among HIV-positive persons increases the risk of progression 
to AIDS and death.  Hepatitis C positive persons co-infected with HIV 
experience acceleration of their liver disease (on average at 15 years 
following transmission compared to 30 years in mono-infected persons) 
and earlier hepatocelluar carcinoma (on average at 18 years following 
transmission).  A major cause of death among HIV and hepatitis C co-
infected persons is end-stage liver disease.  In Ireland, little is published on 
the prevalence of co-infection with HIV and/or hepatitis B and/or hepatitis 
C. Two national prison surveys in the late nineties presented data on co-
infection among prisoners.  Prevalence was determined using antibody 
assays of oral fluid.  Figure 5 shows the inter-relationship between the 
three infections for participants in the inmates survey: 38.5% (459/1193) 
Figure 5   Number of prisoners who tested positive for anti-HBc, anti-
HCV and anti-HIV and the overlap between infections in a prison inmates 
survey, 1998
Adapted from Allwright et al.31  
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of prisoners tested positive for antibodies to one or more virus. Almost 
9% (104/1193) tested positive for more than one virus.  Most of those 
who tested positive for anti-HBc or anti-HIV also had antibodies to one 
or more of the other two viruses (94/104, 90.4%, and 20/24, 83.3%, 
respectively), while 22.9% (101/441) of those testing positive for anti-
HCV had an additional infection.  
As mentioned earlier, Brennan et al.64 ascertained that there were 6,085 
discharges from acute hospitals with hepatitis C as a primary or secondary 
diagnosis recorded by the Hospital In-Patient Enquiry scheme between 
1999 and 2001.  This scheme is an event-based register so cases may be 
represented more than once.  Of the 6,085 cases: 
 • 7% also had a diagnosis of hepatitis B recorded;
 • 24% also had a diagnosis of HIV/AIDS recorded.
These data suggest the existence of co-infection with blood-borne viruses.  
It is important to note injecting drug user status was not systematically 
recorded for all of these cases.  
 The drugs used to manage HIV may lead to increased hepatotoxicity 
in hepatitis C positive persons.74 According to an international working 
group, these patients need to be managed by a team with expertise in 
infectious disease and hepatology.  Both infections require treatment, but 
the approach will differ depending on the patient factors, such as age, 
body mass index, viral load, genotype, level of fibrosis and CD4 cell count. 
According to the international literature, barriers to treatment include 
active polysubstance or alcohol use. This is because active substance users 
demonstrate poorer compliance with treatment and higher discontinuation 
rates. Treatment for HIV and hepatitis C co-infection is available at St 
James’s Hospital, Beaumont Hospital, Mater Misericordiae Hospital and 
University College Hospital, Cork.  
Blood-borne viral infections among injecting 
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8  Conclusion
Hepatitis C is endemic among injecting drug users in Ireland and its 
incidence is higher that in populations of injecting drug users living in 
other countries, indicating that current harm reduction strategies are not 
effective in containing hepatitis C. It is the most common blood-borne 
infectious disease among injecting drug users in Ireland. The number 
of newly diagnosed cases of HIV among injecting drug users increased 
in 1999 and remained at a higher level since, indicating an increase in 
unsafe injecting practices that requires investigation. Among injectors, the 
prevalence of hepatitis B has remained relatively stable, possibly due to 
access to an effective vaccine. Access to and uptake of treatment for HIV 
and hepatitis C are less than desired, although small studies have shown 
that specific interventions can prove effective. This is an area that requires 
investment. The limited data available indicate that a number of injecting 
drug users are infected with more than one blood-borne virus. It has also 
been suggested that alcohol consumption among older opiate users has 
increased and this requires investigation.  Alcohol consumption and dual 
infection are two factors that decrease survival rates among hepatitis C 
infected injecting drug users.  
The data presented in this Overview indicate that there is a need for: 
 • Data on newly diagnosed cases of hepatitis C by risk factor status. 
 •  A register to quantify the incidence and prevalence of hepatitis C 
for all heroin and cocaine users, including those who are in harm 
reduction and treatment services. The register should also permit 
the assessment of main risk factors (including drug-administration 
routes and prison exposure), treatment uptake and outcomes. 
 •  Strategies to increase uptake of and compliance with HIV and 
hepatitis C therapy in both prison and community settings, and 
these need to be monitored. 
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 •  The medical consequences of hepatitis C and the interventions 
required to deal with this infection among injecting drug users to be 
estimated. 
 • Further improvement in the coverage of hepatitis B vaccination. 
 •  A system to monitor the national hepatitis B vaccine uptake to 
estimate coverage among prisoners, injecting drug users and sex 
workers.  
 •  The effectiveness of needle exchange, opiate detoxification and 
opiate maintenance programmes in stabilising and reducing the 
incidence of hepatitis C to be quantified.  
Blood-borne viral infections among injecting 
drug users in Ireland, 1995 to 2005
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